132 related articles for article (PubMed ID: 2511358)
1. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
Sameshima T; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
[TBL] [Abstract][Full Text] [Related]
2. [Definitive diagnosis of early malignant melanoma lesions by the quantitative analysis of 5-S-cysteinyldopa in the tissue and touch fluorescence method].
Kanematsu S; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 Jun; 99(7):783-91. PubMed ID: 2511360
[TBL] [Abstract][Full Text] [Related]
3. [Pigmented spindle cell nevus and pigmented Spitz nevus--clinical and histopathological study on pigmented Spitz nevus, and its differentiation from early melanoma by fluorescence method and measurement of 5-S-CD level in the lesion].
Takeuchi M; Morishima T
Nihon Hifuka Gakkai Zasshi; 1990 Oct; 100(11):1153-65. PubMed ID: 2273578
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis of amelanotic malignant melanoma by means of the fluorescence method (Falck & Hillarp) and determination of 5-S-cysteinyldopa in the lesions].
Morishima T; Fukada E; Nagashima N
Nihon Hifuka Gakkai Zasshi; 1983 Jan; 93(1):51-4. PubMed ID: 6408288
[No Abstract] [Full Text] [Related]
5. Studies on amelanotic melanoma with the fluorescence method (Falck and Hillarp) and biochemical analysis of 5-S-cysteinyldopa in the tissues.
Morishima T; Tatsumi F; Fukada E; Watanabe M; Nagashima N; Hanawa S
Arch Dermatol Res; 1983; 275(5):329-33. PubMed ID: 6419680
[TBL] [Abstract][Full Text] [Related]
6. 5-S-cysteinyldopa in urine and tumors.
Hara H; Chino K; Kawanami T; Sameshima T; Morishima T
J Dermatol; 1992 Nov; 19(11):806-8. PubMed ID: 1293167
[TBL] [Abstract][Full Text] [Related]
7. [Contents of cysteinyldopa isomers and DOPA in lesions of malignant melanoma (author's transl)].
Morishima T; Saito M; Fujita M; Fukada E; Nagashima N; Hanawa S
Nihon Hifuka Gakkai Zasshi; 1982 Feb; 92(2):157-9. PubMed ID: 6806514
[No Abstract] [Full Text] [Related]
8. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
9. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
Agrup G; Agrup P; Andersson T; Hafström L; Hansson C; Jacobsson S; Jönsson PE; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1979; 59(5):381-8. PubMed ID: 93360
[TBL] [Abstract][Full Text] [Related]
10. Detection and quantitation of 5-S-cysteinyldopa in melanotic and amelanotic melanoma in comparison with nonpigment cell tumors and it's urinary excretion.
Mojamdar M; Ichihashi M; Mishima Y
J Dermatol; 1979 Dec; 6(6):379-82. PubMed ID: 120380
[No Abstract] [Full Text] [Related]
11. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
Isabel Zhu Y; Fitzpatrick JE
J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
[TBL] [Abstract][Full Text] [Related]
12. [5-S-cysteinyldopa as a tumor marker for primary uveal malignant melanoma].
Goto H; Tenou T; Kudo H; Iwasaki T; Muramatsu R; Usui M; Wakamatsu K; Ito S
Nippon Ganka Gakkai Zasshi; 1998 May; 102(5):319-26. PubMed ID: 9619024
[TBL] [Abstract][Full Text] [Related]
13. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
Paul E; Graef V; Ruppel R
Z Hautkr; 1980 Dec; 55(23):1543-60. PubMed ID: 6782780
[TBL] [Abstract][Full Text] [Related]
14. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
Morishima T; Tatsumi F; Fukada E; Saito M; Fujita M; Nagashima N; Hanawa S
Arch Dermatol Res; 1983; 275(2):76-9. PubMed ID: 6409012
[TBL] [Abstract][Full Text] [Related]
15. [Not diagnosable malignant melanomas].
Neuber H; Lippold A; Hundeiker M
Hautarzt; 1991 Apr; 42(4):220-2. PubMed ID: 1860796
[TBL] [Abstract][Full Text] [Related]
16. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression.
Horikoshi T; Ito S
J Dermatol; 1992 Nov; 19(11):809-13. PubMed ID: 1293168
[TBL] [Abstract][Full Text] [Related]
17. 5-S-cysteinyldopa in diagnosis and treatment of human malignant melanomas and ultrastructural observations.
Aubert C; Rosengren E; Rorsman H; Rouge F; Foa C; Lipcey C
Eur J Cancer (1965); 1977 Nov; 13(11):1299-308. PubMed ID: 590287
[No Abstract] [Full Text] [Related]
18. Free and bound 5-S-cysteinyldopa and dopa in human malignant melanomas.
Agrup G; Hansson C; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1978; 58(3):270-2. PubMed ID: 78645
[TBL] [Abstract][Full Text] [Related]
19. Intracellular distribution of dopa and 5-S-cysteinyldopa in Harding-Passey melanoma.
Agrup G; Falck B; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1977; 57(4):313-5. PubMed ID: 70922
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of teledermatology for pigmented neoplasms.
Warshaw EM; Lederle FA; Grill JP; Gravely AA; Bangerter AK; Fortier LA; Bohjanen KA; Chen K; Lee PK; Rabinovitz HS; Johr RH; Kaye VN; Bowers S; Wenner R; Askari SK; Kedrowski DA; Nelson DB
J Am Acad Dermatol; 2009 Nov; 61(5):753-65. PubMed ID: 19679375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
